In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Smith & Nephew withdraw 185 BHR (Birmingham Hip Resurfacing) implants:

This article was originally published in Clinica

Executive Summary

Smith & Nephew has recalled 185 of its Birmingham Hip Resurfacing system after discovering that the implants had been incorrectly packaged by the subcontractor. The mistake led to different sized acetabular cups being mixed together. S&N said the error was limited to a small number of batches and that several implants have already been recovered in their packaging. The company added that it has warned, or is in the process of warning, all hospitals that have received the implants and are -working closely" with surgeons and patients on the appropriate corrective action. The UK and US regulatory authorities have also been notified about the recall.

You may also be interested in...



The COVID-19 Effect: Medicare Part B Oncology Drug Claims Down 40% Through April

Study commissioned by the PhRMA underscores concerns about how the coronavirus has disrupted use of physician-administered drugs.

NCI Is Being 'Flexible' With COVID-19 Clinical Trial Protocols

At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.

US FDA Waives Warning Cap Requirement For Neuromuscular Agents As Demand Outranks Safety Worries

COVID-driven supply shortages were both the cause of and solution to production deficiencies for manufacturers of neuromuscular blocking agents; US FDA is permitting Mylan, Gland, and Fresenius Kabi to distribute vecuronium bromide and rocuronium bromide even though they do not have the paralyzing agent’ warning on the caps since the products are in high demand at ICUs. The appropriately embossed caps were unavailable due to supply chain disruptions caused by the pandemic.

Topics

UsernamePublicRestriction

Register

LL044113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel